Director TitleAgeSince
Director/Board Member - 2010-09-30
Director/Board Member - 2010-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+179,900.00%-14.29% - - 172K
-2.81%+0.36%+23.39%+73.94% 50.05B
-0.77%+0.04%+52.08%+119.10% 40.29B
+0.56%+3.85%+17.83%+90.21% 12.17B
+0.98%+0.07%-10.35%+14.26% 11.96B
+0.57%+1.73%+31.59%+153.11% 9.25B
-0.15%-1.87%+25.21%+46.24% 7.62B
-0.39%+2.93%+28.21%+226.32% 7.36B
-0.34%-0.98%+44.49%-11.39% 7.21B
-0.13%-0.16%-40.47%+15.85% 5.26B
Average +17,989.66%+1.16%+19.11%+80.85% 16.8B
Weighted average by Cap. -0.98%+1.81%+27.53%+87.33%
Logo Pivotal Therapeutics Inc.
Pivotal Therapeutics Inc is a Canada-based specialty pharmaceutical company with a focus on optimizing Omega-3 therapy for cardiovascular disease and overall health. The Company's lead product VASCAZEN is used to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase in high-density lipoprotein- Cholesterol (HDL-C) without a negative impact on the low density lipoprotein cholesterol (LDL-C) lipid profile. Its second product, OMAZEN is a greater than 90% pure, pharmaceutical grade Omega-3 commercialized for sale and distribution in Canada only for the maintenance of health.
Employees
-
  1. Stock Market
  2. Stocks
  3. PVTTF Stock